Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2007-12-06

Clinical Trial Update: Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of Etanercept 50 mg once weekly for psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Etanercept (etanercept)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Psoriasis | Phase 3 | Status: COMPLETED